Group 1: I-Mab Biopharma and Taysha Gene Therapies - I-Mab Biopharma will change its name to NovaBridge Biosciences and pursue an initial public offering in Hong Kong, transforming into a "hub-and-spoke" company with drugmaking subsidiaries [2] - NovaBridge will have a newly formed "spoke" called Visara, which will acquire an experimental eye drug currently in Phase 2 testing in China [2] - Taysha Gene Therapies has regained rights to an experimental gene therapy for Rett Syndrome after Astellas Pharma declined to license the treatment, which has helped Taysha secure a breakthrough therapy designation from the FDA [2] Group 2: Funding and Collaborations - Veradermics raised $140 million in a Series C round to fund the development of an oral version of minoxidil, with funding led by SR One and participation from at least 10 other firms [2] - Sanofi announced a collaboration with EVOQ Therapeutics to discover new drugs that induce "immune tolerance" in autoimmune conditions, with EVOQ potentially receiving over $500 million in payments and royalties [2]

some personal newsexcited to reveal that I'm starting the microstrategy for rogainewe will buy all the rogaine in the world, drive the prices up, and ensure mass adoption of baldnessmore to come! ...